Lista de obras -

ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?

artículo científico publicado en 2014

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

artículo científico publicado en 2014

Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).

artículo científico publicado en 2013

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE

artículo científico publicado en 2014

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

artículo científico

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) ⬇️

artículo científico publicado el 1 de marzo de 2011

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

artículo científico publicado en 2015

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas

artículo científico publicado en 2013

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

artículo científico publicado en 2017

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

article

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

artículo científico publicado en 2014

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group

artículo científico publicado en 2017

Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.

artículo científico publicado en 2015

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

artículo científico publicado en 2016

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

artículo científico publicado en 2018

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

artículo científico publicado en 2014

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

artículo científico publicado en 2016

The TAILOR study: to agree or to disagree?

scientific article published on 26 March 2014

The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases

artículo científico publicado en 2017

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

artículo científico publicado en 2016

Lista de obras de

ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) ⬇️

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group

Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

The TAILOR study: to agree or to disagree?

The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.